kynurenine has been researched along with Brain Neoplasms in 19 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These observations provide evidence for altered tryptophan uptake in contralateral cortical and thalamic brain regions in glioma patients after initial therapy, suggesting treatment effects on the serotonergic system." | 7.80 | Clinical significance of tryptophan metabolism in the nontumoral hemisphere in patients with malignant glioma. ( Barger, GR; Chakraborty, PK; Juhász, C; Kamson, DO; Lee, TJ; Mittal, S; Muzik, O; Robinette, NL; Snyder, M; Varadarajan, K, 2014) |
| " Here we report that kynurenine produced by glioblastoma cells activates aryl hydrocarbon receptor (AHR) in TAMs to modulate their function and T cell immunity." | 3.91 | Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. ( Antel, J; Barroso, A; Chao, CC; de Lima, KA; Farez, MF; Gabriely, G; Getz, G; Ghannam, S; Gutiérrez-Vázquez, C; Healy, L; Kenison, J; Mascanfroni, ID; Mayo, L; Prat, A; Quintana, FJ; Reardon, DA; Robson, SC; Rothhammer, V; Rothweiler, S; Sherr, D; Takenaka, MC; Tjon, EC; Vandeventer, T; Weiner, HL; Wheeler, MA; Zandee, S; Zhang, H, 2019) |
| " The AhR and its ligands also inhibit colon carcinogenesis, but it has been reported that the AhR and its ligand kynurenine enhance glioblastoma (GBM)." | 3.91 | The aryl hydrocarbon receptor is a tumor suppressor-like gene in glioblastoma. ( Cheng, Y; Jin, UH; Karki, K; Michelhaugh, SK; Mittal, S; Safe, S, 2019) |
| "We examined the protein expression levels (in 73 gliomas and 48 meningiomas) of the KP rate-limiting enzymes indoleamine 2,3-dioxygenase (IDO) 1, IDO2, and tryptophan 2,3-dioxygenase (TDO2), as well as, the aryl hydrocarbon receptor (AhR), a carcinogenic transcription factor activated by KP metabolites." | 3.88 | Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors. ( Ali-Fehmi, R; Fadel, HA; Guastella, AR; Juhász, C; Kiousis, S; Klinger, NV; Kupsky, WJ; Michelhaugh, SK; Mittal, S, 2018) |
| "These observations provide evidence for altered tryptophan uptake in contralateral cortical and thalamic brain regions in glioma patients after initial therapy, suggesting treatment effects on the serotonergic system." | 3.80 | Clinical significance of tryptophan metabolism in the nontumoral hemisphere in patients with malignant glioma. ( Barger, GR; Chakraborty, PK; Juhász, C; Kamson, DO; Lee, TJ; Mittal, S; Muzik, O; Robinette, NL; Snyder, M; Varadarajan, K, 2014) |
| "Primary brain tumors, both malignant and benign, are diagnosed in adults at an incidence rate of approximately 23 people per 100 thousand." | 2.66 | The Role of Aryl Hydrocarbon Receptor (AhR) in Brain Tumors. ( Grishanova, AY; Perepechaeva, ML, 2020) |
| "Targeting the KP in brain tumors may represent a viable strategy likely to prevent QUIN-induced neurotoxicity and KYN and 3-HAA-mediated immune suppression." | 2.48 | The kynurenine pathway in brain tumor pathogenesis. ( Adams, S; Bessede, A; Bessesde, A; Braidy, N; Brew, BJ; Grant, R; Guillemin, GJ; Teo, C, 2012) |
| "The data indicate that, in mice with brain tumors, youth conveys an advantage to survival." | 1.43 | Advanced age negatively impacts survival in an experimental brain tumor model. ( Genet, M; Gritsina, G; James, CD; Ladomersky, E; Lauing, KL; Wainwright, DA; Wu, M; Zhai, L, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (68.42) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Obara-Michlewska, M | 1 |
| Mohapatra, SR | 1 |
| Sadik, A | 1 |
| Tykocinski, LO | 1 |
| Dietze, J | 1 |
| Poschet, G | 1 |
| Heiland, I | 1 |
| Opitz, CA | 2 |
| Riess, C | 1 |
| Schneider, B | 1 |
| Kehnscherper, H | 1 |
| Gesche, J | 1 |
| Irmscher, N | 1 |
| Shokraie, F | 1 |
| Classen, CF | 1 |
| Wirthgen, E | 1 |
| Domanska, G | 1 |
| Zimpfer, A | 1 |
| Strüder, D | 1 |
| Junghanss, C | 1 |
| Maletzki, C | 1 |
| Perepechaeva, ML | 1 |
| Grishanova, AY | 1 |
| Vázquez Cervantes, GI | 1 |
| Pineda, B | 1 |
| Ramírez Ortega, D | 1 |
| Salazar, A | 1 |
| González Esquivel, DF | 1 |
| Rembao, D | 1 |
| Zavala Vega, S | 1 |
| Gómez-Manzo, S | 1 |
| Pérez de la Cruz, G | 1 |
| Pérez de la Cruz, V | 1 |
| Guastella, AR | 2 |
| Michelhaugh, SK | 3 |
| Klinger, NV | 2 |
| Fadel, HA | 1 |
| Kiousis, S | 1 |
| Ali-Fehmi, R | 1 |
| Kupsky, WJ | 2 |
| Juhász, C | 3 |
| Mittal, S | 4 |
| Takenaka, MC | 1 |
| Gabriely, G | 1 |
| Rothhammer, V | 1 |
| Mascanfroni, ID | 1 |
| Wheeler, MA | 1 |
| Chao, CC | 1 |
| Gutiérrez-Vázquez, C | 1 |
| Kenison, J | 1 |
| Tjon, EC | 1 |
| Barroso, A | 1 |
| Vandeventer, T | 1 |
| de Lima, KA | 1 |
| Rothweiler, S | 1 |
| Mayo, L | 1 |
| Ghannam, S | 1 |
| Zandee, S | 1 |
| Healy, L | 1 |
| Sherr, D | 1 |
| Farez, MF | 1 |
| Prat, A | 1 |
| Antel, J | 1 |
| Reardon, DA | 1 |
| Zhang, H | 1 |
| Robson, SC | 1 |
| Getz, G | 1 |
| Weiner, HL | 1 |
| Quintana, FJ | 1 |
| Jin, UH | 1 |
| Karki, K | 1 |
| Cheng, Y | 1 |
| Safe, S | 1 |
| Kamson, DO | 1 |
| Lee, TJ | 1 |
| Varadarajan, K | 1 |
| Robinette, NL | 1 |
| Muzik, O | 2 |
| Chakraborty, PK | 1 |
| Snyder, M | 1 |
| Barger, GR | 1 |
| Adams, S | 2 |
| Teo, C | 2 |
| McDonald, KL | 1 |
| Zinger, A | 1 |
| Bustamante, S | 1 |
| Lim, CK | 1 |
| Sundaram, G | 1 |
| Braidy, N | 2 |
| Brew, BJ | 2 |
| Guillemin, GJ | 3 |
| Polin, LA | 1 |
| Ladomersky, E | 2 |
| Zhai, L | 2 |
| Gritsina, G | 2 |
| Genet, M | 1 |
| Lauing, KL | 2 |
| Wu, M | 2 |
| James, CD | 1 |
| Wainwright, DA | 2 |
| Dostal, CR | 1 |
| Swoap, K | 1 |
| Billingham, LK | 1 |
| McCusker, RH | 1 |
| Binder, DC | 1 |
| Litzenburger, UM | 1 |
| Sahm, F | 1 |
| Ott, M | 1 |
| Tritschler, I | 1 |
| Trump, S | 1 |
| Schumacher, T | 1 |
| Jestaedt, L | 1 |
| Schrenk, D | 1 |
| Weller, M | 1 |
| Jugold, M | 1 |
| Miller, CL | 1 |
| Lutz, C | 1 |
| Radlwimmer, B | 1 |
| Lehmann, I | 1 |
| von Deimling, A | 1 |
| Wick, W | 1 |
| Platten, M | 1 |
| Prendergast, GC | 1 |
| Wszelaki, N | 1 |
| Melzig, MF | 1 |
| Bessede, A | 1 |
| Bessesde, A | 1 |
| Grant, R | 1 |
| Vezzani, A | 1 |
| Gramsbergen, JB | 1 |
| Speciale, C | 1 |
| Schwarcz, R | 1 |
| DeGeorge, FV | 1 |
| Brown, RR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tryptophan Metabolism in Human Brain Tumors[NCT02367469] | 105 participants (Anticipated) | Observational | 2014-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for kynurenine and Brain Neoplasms
| Article | Year |
|---|---|
The tryptophan metabolism, kynurenine pathway and oxidative stress - implications for glioma pathobiology.
Topics: Brain Neoplasms; Glioma; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Oxidative Stress; | 2022 |
The Role of Aryl Hydrocarbon Receptor (AhR) in Brain Tumors.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Disease Management; Disease | 2020 |
The kynurenine pathway in brain tumor pathogenesis.
Topics: Animals; Brain Neoplasms; Glioma; Humans; Kynurenine; Signal Transduction | 2012 |
16 other studies available for kynurenine and Brain Neoplasms
| Article | Year |
|---|---|
Hypoxia Inducible Factor 1α Inhibits the Expression of Immunosuppressive Tryptophan-2,3-Dioxygenase in Glioblastoma.
Topics: Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Gene Expression Regulation, Enzymologic; Glioblasto | 2019 |
Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Cell; Cell Line | 2020 |
Kynurenine Monooxygenase Expression and Activity in Human Astrocytomas.
Topics: Adult; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Enzymolog | 2021 |
Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gl | 2018 |
Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39.
Topics: Animals; Antigens, CD; Apyrase; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Glioblastoma | 2019 |
The aryl hydrocarbon receptor is a tumor suppressor-like gene in glioblastoma.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2019 |
Clinical significance of tryptophan metabolism in the nontumoral hemisphere in patients with malignant glioma.
Topics: Adult; Aged; Brain; Brain Neoplasms; Female; Glioma; Humans; Kynurenine; Magnetic Resonance Imaging; | 2014 |
Involvement of the kynurenine pathway in human glioma pathophysiology.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Astrocytes; Biosynthetic Pathways; Brain Ne | 2014 |
Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma.
Topics: Aged; Animals; Biosynthetic Pathways; Brain Neoplasms; Carbon Radioisotopes; Cell Line, Tumor; Femal | 2016 |
Advanced age negatively impacts survival in an experimental brain tumor model.
Topics: Aging; Animals; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Glioblastoma; Indoleamine | 2016 |
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
Topics: Animals; Brain; Brain Neoplasms; Disease Models, Animal; Glioblastoma; Indoleamine-Pyrrole 2,3,-Diox | 2017 |
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.
Topics: Animals; Autocrine Communication; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progress | 2011 |
Cancer: Why tumours eat tryptophan.
Topics: Animals; Brain Neoplasms; Glioma; Humans; Kynurenine; Receptors, Aryl Hydrocarbon | 2011 |
Research on an in vitro cell system for testing the neurotoxicity of kynurenine pathway metabolites.
Topics: Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Survival; Coloring Agents; Fluorescent | 2011 |
Production of quinolinic acid and kynurenic acid by human glioma.
Topics: 3-Hydroxyanthranilate 3,4-Dioxygenase; 3-Hydroxyanthranilic Acid; Astrocytoma; Brain Neoplasms; Diox | 1991 |
Differences in tryptophan metabolism between breast cancer patients with and without cancer at other sites.
Topics: Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Female; Humans; Kynurenic Acid; Kynurenine; Lung | 1970 |